The development of novel cell therapies requires the latest technologies to create, isolate and characterize the highest value cells. As cell-based therapies expand into areas far beyond monoclonal antibodies, cell line development researchers look for new tools to engage and manage their expanding remit.
Cell line development workflows engage in isolation of single cells (‘clonal derivation’) followed by outgrowth. Productivity measurements and critical quality attributes are employed in the characterization of leading clones for banking in Master Cell Banks.
This webinar explores our two new technologies for cell line development, ICON™ and STUDIUS™. Learn about the practicalities of integrating data-centric decision making into the cell therapy development process and how new levels of assurance, data integrity and process management can build into a more confident investigational new drug (IND) submission.
Duncan Borthwick has a PhD from the University of Edinburgh and University of North Carolina, Chapel Hill Since hanging up his lab coat 20+ years ago, Duncan has worked in thedevelopment of novel instrumentation and products. He heads the Product Management group at Solentim working closely with the R&D, biology and commercial teams working to define the next set of products to support the cell therapy community.
Mark Stockdale is a keen technology consultant. He worked as a Group Leader at Horizon Discovery Ltd, a scientist within Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years of professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs and provides great insight into the future technology requirements in stable cell line development.
Please complete the form below and we’ll instantly send you an email with a link to the presentation:
Please double-check your ‘junk’ folder for the email from our [email protected] address.